Target Poor or Non Binder(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T74570 | Target Info | |||
| Target Name | Inward rectifier potassium channel Kir2.1 (KCNJ2) | ||||
| Synonyms |
hIRK1; Potassium channel, inwardly rectifying subfamily J member 2; Inward rectifier K(+) channel Kir2.1; IRK1; IRK-1; Cardiac inward rectifier potassium channel
Click to Show/Hide
|
||||
| Target Type | Literature-reported Target | ||||
| Gene Name | KCNJ2 | ||||
| Biochemical Class | Inward rectifier potassium channel | ||||
| UniProt ID | |||||
| Poor Binders of This Target (in total, 8 binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
5-[2-[4-[2-[4-(Tetrazol-1-yl)phenyl]acetyl]piperazin-1-yl]ethyl]-3H-2-benzofuran-1-one
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL2441437; SCHEMBL4549136; BDBM50442600
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[1] | |||
| Compound Name |
6-[(1S)-1-Hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
SCHEMBL2896906; CHEMBL3612810; BDBM155928; US9018211, 52
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[2] | |||
| Compound Name |
4-Methyl-5-[2-[4-[2-[6-(tetrazol-1-yl)pyridin-3-yl]acetyl]piperazin-1-yl]ethyl]-3H-2-benzofuran-1-one
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
SCHEMBL4549272; CHEMBL3692706; BDBM162872; US9056859, 72
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[3] | |||
| Compound Name |
8-[(2R)-2-Hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL4069245; SCHEMBL17723589; BDBM50249183
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[4] | |||
| Compound Name |
1,4-Bis[2-(4-nitrophenyl)ethyl]piperazine
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL2146755; SCHEMBL2731306; BDBM50391770; 1,4-Bis(4-Nitrophenethyl)Piperazine
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[5] | |||
| Compound Name |
1-[2-(4-Nitrophenyl)ethyl]piperazine
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL2146754; 1-(4-Nitrophenethyl)Piperazine; 1-(p-nitrophenethyl)piperazine; SCHEMBL2723268; KS-00001NMA; BDBM50391771; MFCD11590789; ZINC19726918; AKOS005845163; DA-01146; FT-0724620
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[5] | |||
| Compound Name |
Auglurant
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
VU0424238; N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide; CHEMBL2386850; UNII-GRN8X62ZW2; GRN8X62ZW2; SCHEMBL12499337; VU238; EX-A2936; BDBM50257064; MFCD28386341; VU 238; 2-PyridinecarboxaMide, N-(5-fluoro-2-pyridinyl)-6-Methyl-4-(5-pyriMidinyloxy)-; HY-16617; CS-0009173; VU 0424238; YU-0424238; J3.655.475D; 2-PyridinecarboxaMide,N-(5-fluoro-2-pyridinyl)-6-Methyl-4-(5-pyriMidinyloxy)-; N-(5-Fluoro-2-pyridinyl)-6-methyl-4-(5-pyrimidinyloxy)-2-pyridinecarboxamide; N-(5-fluoropyridin-2-yl)-6-methyl-4-pyrimidin-5-yloxypyridine-2-carboxamide
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[6] | |||
| Compound Name |
6-Fluoro-2-methyl-3-[(3R,9sS)-octahydro-8-[2-[5-(1H-tetrazol-1-yl)-2-pyridinyl]acetyl]pyrazino[2.1=c][1.4]oxazin-3-yl]benzonitrile
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL3933749; XAN35021; SCHEMBL15036619; BDBM50204281
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[7] | |||
| Click to Show/Hide the Information of All Poor Binders | |||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5829-32. | ||||
| REF 2 | Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation. ACS Med Chem Lett. 2015 May 7;6(7):747-52. | ||||
| REF 3 | Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorg Med Chem Lett. 2016 May 1;26(9):2339-43. | ||||
| REF 4 | Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2559-2566. | ||||
| REF 5 | Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics. ACS Med Chem Lett. 2012 Mar 28;3(5):367-72. | ||||
| REF 6 | Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. J Med Chem. 2017 Jun 22;60(12):5072-5085. | ||||
| REF 7 | Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold. Bioorg Med Chem Lett. 2016 Dec 1;26(23):5695-5702. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.